Marjan Kuijer

National Institute for Public Health and the Environment — Netherlands

Medicine · Health Sciences

11h-index514citations25works5.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(20), COVID-19 Clinical Research Studies(11), Vaccine Coverage and Hesitancy(6), COVID-19 epidemiological studies(4), SARS-CoV-2 detection and testing(4)

Publications25 total

Antibody waning and Bordetella pertussis resurgence after the COVID-19 pandemic in the Netherlands
Nature Communications·2026Open Access
Impact of immunomodulating medication on maternal Tdap vaccination-induced antibodies in infants
Journal of Crohn s and Colitis·2025· 1 citedOpen Access
Development and validation of a high throughput multiplex immunofluorescence assay to detect all human immunoglobulin isotypes and subclasses in human fluids
The Journal of Immunology·2025Open Access
Health characteristics associated with persistence of SARS-CoV-2 antibody responses after repeated vaccinations in older persons over time: the Doetinchem cohort study
Immunity & Ageing·2024· 4 citedOpen Access
Health Characteristics Associated With Persistence of SARS-CoV-2 Antibody Responses After Repeated Vaccinations in Older Persons Over Time: The Doetinchem Cohort Study
2024Open Access
SARS‐CoV‐2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response
Influenza and Other Respiratory Viruses·2024· 11 citedOpen Access
Author response for "SARS‐CoV‐2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response"
2024
Protective mucosal SARS-CoV-2 antibodies in the majority of the general population in the Netherlands
Mucosal Immunology·2024· 7 citedOpen Access
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose
Clinical Microbiology and Infection·2024· 6 citedOpen Access
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial
npj Vaccines·2024· 30 citedOpen Access
Nationwide SARS-CoV-2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era, 2021-2022: an Ongoing Prospective Cohort Study
2023· 4 citedOpen Access
Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial
The Lancet Infectious Diseases·2022· 69 citedOpen Access
Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study
Annals of Internal Medicine·2022· 24 citedOpen Access
Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands
Vaccines·2022· 33 citedOpen Access
Reduced antibody acquisition with increasing age following vaccination with BNT162b2: results from a large study performed in the general population aged 12 to 92 years
2022Open Access
SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA or vector-based vaccination in the general Dutch population show distinct kinetics
Scientific Reports·2022· 24 citedOpen Access
Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?
Vaccine·2022· 67 citedOpen Access
SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA- versus vector-based vaccination in the general Dutch population
2021· 1 citedOpen Access
Seropositivity to Nucleoprotein to detect SARS-CoV-2 infections: a tool to detect breakthrough infections after COVID-19 vaccination
2021· 3 citedOpen Access
Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy
2021· 7 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Gerco den Hartog(20), Gaby Smits(12), Fiona van der Klis(11), Robert S. van Binnendijk(11), Alienke J. Wijmenga‐Monsuur(9), Nynke Y. Rots(8), Denise Wong(8), Eric R. A. Vos(8), Rob van Binnendijk(6), Lotus L. van den Hoogen(6), Cheyenne C. E. van Hagen(6), Jeffrey van Vliet(6), Joanna Kaczorowska(6), Corine H. GeurtsvanKessel(5), Hester E. de Melker(5), Geert V.T. Roozen(5), Corine Prins(5), Jacqueline J. Janse(5), Mariet C.W. Feltkamp(5), Meta Roestenberg(5)